Aging studies are—by necessity—lengthy, resource intensive, and require advance planning. Download this guide to learn which considerations are essential to designing studies with aged mice
Friedreich’s Ataxia (FA) is a progressive, autosomal recessive, neurodegenerative disease. Its onset, typically around puberty, is marked by a rapid progression, with most patients relying on a wheelchair by their late 20s. FA is caused by a trinucleotide (GAA) repeat expansion mutation within intron 1 of the frataxin gene. The severity of the disease directly correlates to the size of the expansion.
While it cannot be stopped completely, genetic drift and the impact on scientific discovery can be minimized through careful and thoughtful colony management practices. Download our new whitepaper to learn more.
Acute myeloid leukemia is a complex hematological malignancy with high molecular heterogeneity. JAX offers ten AML patient-derived xenograft (PDX) models with varying mutational profiles and treatment histories. These models are available for analyzing the effectiveness of potential new drugs–alone or in combination–to treat AML. These PDX models (Townsend et al.) have been engrafted in the highly immunodeficient NSG-SGM3 (stock #013062), the mouse strain that most effectively engrafts human myeloid leukemia.
To support a collaboration between Dr. Cat Lutz of The Jackson Laboratory and the Friedrich’s Ataxia Research Alliance, our Model Generation Services (MGS) team undertook a project to create a conditional knockout allele of the Frataxin (Fxn) gene using the Cre-loxP Recombination System.
Mice are used extensively in aging research due to their genetic and physiological similarity to humans. Aging studies are—by necessity—lengthy, resource intensive, and require advance planning. The Jackson Laboratory now offers study-ready cohorts of male and female C57BL/6J mice up to 78 weeks of age. This article is intended to support investigators who may be new users of this resource and more experienced researchers who may be seeking a quick and useful summary. We will review special considerations for maximizing the translational value of data collected from aged mice and highlight resources for identifying and implementing best practices.
Genome editing with CRISPR/Cas9 enables the generation of new mouse models with unprecedented speed and simplicity. The Jackson Laboratory was an early adopter of CRISPR/Cas9 technology for mouse model development, and in this brief guide we describe the technology and lessons learned to generate knockouts and knockins in more than a dozen different genetic backgrounds.
NSG™ mice are a proven host for engraftment of human tumors or establishment of human immunity following hematopoietic stem cell transplantation. This guide explains why the interactions between human immune cells and tumors are paramount when devising treatment strategies that prevent tumor evasion of immune cells and improve cytotoxic responses.The Jackson Laboratory offers efficacy studies in multiple human systemic lupus erythematosus (SLE) models, including the two most commonly used spontaneous mouse models, MRL/MpJ-Faslpr/J and NZBWF1/J.
This poster compares the benefits and considerations for the top 10 metabolic disease mouse models from JAX.
Mouse In Vitro Fertilization (IVF) can be used to rapidly expand mouse lines from a few males that carry the desired genotype or to maintain strains with poor breeding efficiency. This guide describes a detailed method using acidified Tyrode solution to open the zona pellucida and increase the fertilization capacity of frozen mouse sperm.
This guide summarizes the guidelines for preclinical testing and colony management of ALS mice discusses considerations for preclinical studies using SOD1 mice, colony management, QPCR protocol for determining copy number, and more.
Download a listing of MHC H2 Haplotypes and Histocompatibility Haplotypes and Loci for JAX® Mice.
The Jackson Laboratory is the global leader in mammalian genetics modeling and education, and has been a driving force in supporting scientific breakthroughs for over 80 years.
This booklet explains how JAX® Mice, Clinical and Research Services for oncology are essential tools for the in vivo study of hematological malignancies, neoplasia, regenerative medicine, and immune-oncology. Our PDX models and other next-generation cancer modeling platforms allow you to address critical questions in oncology research, such as unexplained drug resistance, drug efficacy, genomic heterogeneity in solid tumor, and the role of the immune system in drug response.
This portfolio explains our optimized Patient Derived Xenograft (PDX) efficacy studies utilizing its PDX Live™ library. These select tumors are kept at low passage in live donor mice, enabling fast-tracked efficacy testing studies for pre-clinical cancer drug development, potentially saving months of pre-study time.
This portfolio describes how the fields of optogenetics, transient-sensing (calcium-, voltage-, glutamate-) technologies, and chemogenetics have accelerated over the past 5-10 years - as the tools and techniques have been reduced to practice and applied to fields including behavior, memory, mental illness, and disease.
The JAX Cancer Treatment Profile™ is a targeted panel of 358 cancer related genes and 53 genes known to form fusions associated with various carcinomas, sarcomas and hematologic malignancies; analyzed using next-generation sequencing.
NSG™ mouse model variants are the most highly immunodeficient mice and the models of choice for cancer xenograft modeling, stem cell biology, humanized mice, and infectious disease research. Download this guide to compare NSG™ mouse model strains.
Designing and validating models for the study of neurological diseases presents a unique set of challenges. Experts understand that modeling neurodegenerative diseases may be arduous and can present challenges that need to be addressed when used for preclinical studies (Lutz & Osborne, 2013). In this whitepaper, we will review best practices for using models for neuromuscular diseases to identify molecular targets and to evaluate the efficacy of potential therapeutics.
Type 1 diabetes is a disease characterized by autoimmune destruction of the insulin producing pancreatic beta cells by autoreactive, pathogenic T cells. B lymphocytes play a key role in this process by acting as antigen presenting cells for these T cells. Dr. David Serreze of The Jackson Laboratory was interested in testing the hypothesis that the Aicda gene, which is required for class switch recombination/somatic hypermutation in B lymphocytes, is important in the development of diabetes.
Our syngeneic studies allow you to evaluate the synergistic response of your test article used in conjunction with checkpoint inhibitors or to test novel immunomodulatory compounds
JAX MGS utilized a short oligo-mediated knockin approach to generate a small mouse model panel in which each model carries a mouse allele that has been modified to carry a different, specified amino acid at key orthologous positions identified in the FALS patient analysis.
Clinically relevant humanized FcRn mouse models demonstrate therapeutic half life concordant with human and non-human primates.
NSG™ and NSG™-SGM3 mice engrafted with allogeneic human tumors represent a valuable preclinical testing platform for immuno-oncology. Here we employ four 14-color flow cytometry panels to perform a comprehensive and detailed analysis of the entire immune system. Our results indicate that the triple transgenic NSG™-SGM3 mice exhibit a more completely humanized immune system as compared to NSG™ mice, with specific improvements in the distribution of T-cell subsets and overall representation of the myeloid lineage.
Humanized NSG™ mice are used by researchers and drug discovery scientists as powerful tools to study hematopoiesis, inflammatory disease and viral host-pathogen interactions. These mouse models are accelerating the development of novel therapies in HIV infection and oncology. This guide describes the development of humanized mice and how to select the appropriate model for your research
The definitive resource for anyone working with laboratory mice, this is the 6th edition of The Jackson Laboratory Handbook on Genetically Standardized Mice.
This guide summarizes the history of SMA mouse model development. It describes the original models developed in the laboratories of Drs. Michael Sendtner at the University of Worzburg and Arthur Burghes at Ohio State University, the latest models that allow temporal and tissue specific control of SMN expression, and models under development.
Working jointly with CHDI and PsychoGenics, Inc., we created a valuable guide packed with best practices for managing Huntington’s disease mouse colonies and preclinical research study design considerations.
JAX is the global leader in mouse genetics and husbandry, and has been a driving force in developing and supporting innovative approaches to mouse breeding and reproduction. This booklet explains how our comprehensive colony management solutions are designed to partner with your basic science or commercial drug discovery program to meet your research objectives.
This booklet contains a comprehensive suite of solutions to support your research using neurological mouse models.
This portfolio discusses why PDX models provide a relevant and translatable animal model to study human cancer biology compared to cell-line xenografts. Our PDX program provides tumor models at a lower passage, more accurately reflecting clinical samples compared to other PDX resources.
Patient-derived tumor xenografts in humanized NSG™ and NSG™-SGM3 mice
The JAX ActionSeq™ test is a targeted panel of 212 cancer related genes analyzed using next-generation sequencing. The panel assesses all identified functional variants for clinical relevance, based on associations in the biomedical literature with response or resistance to FDA-approved targeted therapies.
Every patient is unique. So is every patient’s tumor. This one pager explains how advances in high-throughput molecular diagnostics now allow detection of the genetic alterations that are specific to an individual patient’s tumor. By identifying the oncogenic drivers, therapeutic options can be matched to the tumor’s biology.